"We are impressed by China's resilience in economic recovery and advancing a 'dual circulation' strategy combining domestic development and global integration.” Lars Fruergaard Jørgensen, President and CEO, Novo Nordisk said, "In China, Novo Nordisk contributes to local innovation and has achieved robust growth during 2020 as a consequence of increasing domestic demands.”

"COVID-19 has demonstrated a collective obligation to find sustainable ways to reduce the health inequalities that exist on a global scale. In Novo Nordisk, we have strengthened our commitments to better support vulnerable patients and high-risk groups – for example by ensuring the supply of lifesaving medicines and supporting societies and communities worldwide.” he added, "At the same time, we commend China's effective control of the pandemic domestically as well as support to the global community. The Chinese leadership has made a bold call for the need to establish 'a global community of health for all' and Novo Nordisk is ready to be a very active part of the solution.”